WuXi Biologics (Cayman) Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WXIBF research report →
Price Chart
About the company
WuXi Biologics (Cayman) Inc. provides extensive global services, spanning the entire biopharmaceutical process from drug discovery to advanced development and manufacturing, catering to clients in China, North America, Europe, and other international markets. The company also offers expert consultation in biopharmaceutical technology, facilitates international sales contracting, develops and performs advanced testing services, and manages sales and marketing initiatives.
- CEO
- Zhisheng Chen
- IPO
- 2018
- Employees
- 13,252
- HQ
- Wuxi, JS, CN
Get TickerSpark's AI analysis on WXIBF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $29.54B
- P/E
- 37.98
- Fwd P/E
- 4.83
- PEG
- 1.92
- P/S
- 8.06
- P/B
- 3.92
- EV/EBITDA
- 19.45
- Div Yield
- 0.00%
- Gross Margin
- 47.47%
- Op Margin
- 32.36%
- Net Margin
- 21.20%
- ROE
- 10.51%
- ROIC
- 10.60%
Latest fiscal year · YoY change
- Revenue
- $21.23B+13.7%
- Gross Profit
- $9.76B+27.6%
- Op Income
- $6.47B
- Net Income
- $4.78B+42.5%
- EPS
- $1.19+45.1%
- OCF Growth
- +22.5%
- FCF Growth
- +117.4%
- 52W High
- $7.49
- 52W Low
- $2.74
- 50D MA
- $6.05
- 200D MA
- $4.90
- Beta
- 0.60
- RSI (14)
- 74
- Avg Volume
- 1.82K
No earnings-call transcripts are available for WXIBF yet.
- Free Float
- 90.0%
- Shares Outstanding
- 4.14B
- Float Shares
- 3.73B
Held by 2 ETFs
Biggest fund positions in WXIBF by dollar value.
Our WXIBF coverage
Recent articles, reports, and earnings notes.
No research on WXIBF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate WXIBF report →Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.